Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients Article

Sylvester, Robert K, Steen, Preston, Tate, John M et al. (2011). Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients . ANTI-CANCER DRUGS, 22(1), 104-110. 10.1097/CAD.0b013e3283407e9f

cited authors

  • Sylvester, Robert K; Steen, Preston; Tate, John M; Mehta, Minesh; Petrich, Ryan J; Berg, Alexander; Kolesar, Jill

sustainable development goals

authors

publication date

  • January 1, 2011

webpage

published in

keywords

  • ADJUVANT TEMOZOLOMIDE
  • APLASTIC-ANEMIA
  • CONCOMITANT
  • GENE POLYMORPHISMS
  • GLIOBLASTOMA
  • Life Sciences & Biomedicine
  • MDR1
  • MGMT PROMOTER METHYLATION
  • O(6)-methylguanine-DNA-methyltransferase polymorphism
  • O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY
  • Oncology
  • Pharmacology & Pharmacy
  • RADIOTHERAPY
  • Science & Technology
  • THERAPY
  • epigenetic silencing
  • glioblastoma
  • multidrug resistance gene
  • myelosuppression
  • temozolomide

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

start page

  • 104

end page

  • 110

volume

  • 22

issue

  • 1